Skip to content

Study · Observational study · n = 25 · 2024

4 results

Long-term weight outcomes in patients treated with liraglutide 3.0 mg in real-world clinical practice.

Grannell A, Al-Najim W, le Roux C

Clinical obesity24 Aug 2023Cited by 7 (Europe PMC)

PMID37615384 (opens in a new tab)DOI10.1111/cob.12622 (opens in a new tab)PepBankPUB-37615384
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanObservational studyOther

    In 25 patients with obesity treated with liraglutide 3.0 mg, weight loss was associated with weight change from the artificial nadir (R2 = 0.39).

    In plain wordsIn 25 people with obesity on liraglutide, weight loss was linked to later weight change.

    Peptide
    Liraglutide
    Outcome
    Not applicableAssociation of weight loss with weight change from nadir
    Study

    n = 25

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    3.0 mg · 78 weeksAs given in this study (human).

    Measurements

    R2
    0.39
    weight loss vs weight change from nadir

    Source sentences

    Summary
    Weight loss (R2  = 0.39, p < .001), fat mass loss (R2  = 0.32, p = .003) and fat-free mass loss (R2  = 0.19, p = .03) were all associated with weight change from artificial nadir, which was, on average, 3.8 kg.
    1 context sentence
    Summary · context
    The study included 25 patients treated with multi-modal care that included liraglutide 3.0 mg over a period of 78 weeks.
  2. 02HumanObservational studyOther

    In 25 patients treated with liraglutide 3.0 mg, fat mass loss was associated with weight change from the artificial nadir (R2 = 0.32).

    In plain wordsIn 25 people on liraglutide, losing fat mass was linked to later weight change.

    Peptide
    Liraglutide
    Outcome
    Not applicableAssociation of fat mass loss with weight change from nadir
    Study

    n = 25

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    3.0 mg · 78 weeksAs given in this study (human).

    Measurements

    R2
    0.32
    fat mass loss

    Source sentences

    Summary
    Weight loss (R2  = 0.39, p < .001), fat mass loss (R2  = 0.32, p = .003) and fat-free mass loss (R2  = 0.19, p = .03) were all associated with weight change from artificial nadir, which was, on average, 3.8 kg.
    1 context sentence
    Summary · context
    The study included 25 patients treated with multi-modal care that included liraglutide 3.0 mg over a period of 78 weeks.
  3. 03HumanObservational studyOther

    In 25 patients treated with liraglutide 3.0 mg, fat-free mass loss was associated with weight change from the artificial nadir (R2 = 0.19).

    In plain wordsIn 25 people on liraglutide, losing fat-free mass was linked to later weight change.

    Peptide
    Liraglutide
    Outcome
    Not applicableAssociation of fat-free mass loss with weight change from nadir
    Study

    n = 25

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    3.0 mg · 78 weeksAs given in this study (human).

    Measurements

    R2
    0.19
    fat-free mass loss

    Source sentences

    Summary
    Weight loss (R2  = 0.39, p < .001), fat mass loss (R2  = 0.32, p = .003) and fat-free mass loss (R2  = 0.19, p = .03) were all associated with weight change from artificial nadir, which was, on average, 3.8 kg.
    1 context sentence
    Summary · context
    The study included 25 patients treated with multi-modal care that included liraglutide 3.0 mg over a period of 78 weeks.
  4. 04HumanObservational studyOther

    After adjustment, only fat mass loss was associated with weight regain in patients treated with liraglutide 3.0 mg (R2 = 0.32).

    In plain wordsAfter adjustment, only fat mass loss was linked to weight regain in people on liraglutide.

    Peptide
    Liraglutide
    Outcome
    Not applicableAdjusted association of fat mass loss with weight regain
    Study

    n = 25

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    3.0 mg · 78 weeksAs given in this study (human).

    Measurements

    R2
    0.32
    fat mass loss, adjusted

    Source sentences

    Summary
    For body composition, after adjustment, only fat mass loss was associated weight regain (R2  = 0.32, p = .01).
    1 context sentence
    Summary · context
    The study included 25 patients treated with multi-modal care that included liraglutide 3.0 mg over a period of 78 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.